Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 1/2015

01-01-2015 | Gastrointestinal Cancers (B Czito, Section Editor)

Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy

Authors: Felipe A. Calvo, Claudio V. Sole, Hugo Marsiglia, Eduardo Alvarado, Carlos Ferrer, Brian Czito

Published in: Current Oncology Reports | Issue 1/2015

Login to get access

Abstract

The integration of intraoperative radiotherapy (IORT) into the multimodal treatment of gastrointestinal cancer is feasible and leads to high rates of local control. In-field tumoral control using IORT-containing strategies can be achieved in over 90 % of most cases, regardless of the site or status of the tumor (primary or recurrent). Electron beam IORT, or intraoperative electron radiation therapy, is the dominant technology used in institutions reporting data in publications the 21st century. Neither surgery nor systemic therapy is compromised by the integration of IORT-containing radiotherapy.
Literature
1.
2.
Smith BD, Haffty BG, Wilson LD, et al. The future of radiation Oncology in the United States from 2010 to 2020: will supply keep pace with demand? J Clin Oncol. 2010;31:4151–7.
3.••
Gunderson LL, Ashman JB, Haddock MG, et al. Integration of radiation oncology with surgery as combined-modality treatment. Surg Oncol Clin N Am. 2013;22:405–32. Patient selection and contemporary integration of radiation (EBRT and IORT) and surgery has become the standard treatment for patients with locally advanced primary cancers and those with local-regional relapse.PubMedCrossRef
4.
Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–39.PubMedCrossRef
5.••
Debenham BJ, Hu KS, Harrison LB. Present status and future directions of intraoperative radiotherapy. Lancet Oncol. 2013;14:e457–64. Intraoperative radiotherapy is part of the multimodality armamentarium to treat common tumour sites in the primary or recurrent setting. Several new techniques, radiobiology, and physics of intraoperative radiotherapy are currently being explored.PubMedCrossRef
6.
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33.PubMedCrossRef
7.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;335:11–20.CrossRef
8.
Calvo FA, Sole CV, Obregón R, et al. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol. 2013;15:443–9.PubMedCrossRef
9.
Zhang Q, Tey J, Peng L, et al. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. Radiother Oncol. 2012;102:51–5.PubMedCrossRef
10.
Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys. 2008;70:715–21.PubMedCrossRef
11.
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RH, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2001;12:681–92.CrossRef
12.
Hosokawa M, Shirato H, Ohara M, et al. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer. 1999;86:6–13.PubMedCrossRef
13.
Murakami M, Kuroda Y, Nakajima T, et al. Intraoperative radiotherapy for the abdominal lymphatic system in patients with esophageal carcinoma. Dis Esophagus. 1999;12:270–5.PubMedCrossRef
14.
Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, et al. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus. 2006;19:487–95.PubMedCrossRef
15.
Calvo FA, Sole CV, Obregón R, et al. Postchemoradiation resected locally advanced esophageal and gastroesophageal junction carcinoma: long-term outcome with or without intraoperative radiotherapy. Ann Surg Oncol. 2013;20:1962–9.PubMedCrossRef
16.
Azinovic I, Calvo FA, Puebla F, et al. Long-term normal tissue effects of intraoperative electron radiation therapy (IOERT): late sequelae, tumor recurrence, and second malignancies. Int J Radiat Oncol Biol Phys. 2001;49:597–604.PubMedCrossRef
17.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiation and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet. 2001;358:1576–85.PubMedCrossRef
18.
Calvo FA, Valentini V. Radiotherapy for pancreatic cancer: systematic nihilism or intraoperative realism. Radiother Oncol. 2008;87:314–7.PubMedCrossRef
19.
Valentini V, Calvo F, Reni M, Krempien R, Sedlmayer F, Buchler MW, et al. Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol. 2009;91:54–9.PubMedCrossRef
20.
Ogawa K, Karasawa K, Ito Y, Ogawa Y, Jingu K, Onishi H, et al. Intraoperative radiotherapy for resected pancreatic cancer: a multi-institutional retrospective analysis of 210 patients. Int J Radiat Oncol Biol Phys. 2010;77:734–42.PubMedCrossRef
21.
Jingu K, Tanabe T, Nemoto K, Ariga H, Umezawa R, Ogawa Y, et al. Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan. Int J Radiat Oncol Biol Phys. 2012;83:507–11.CrossRef
22.
Calvo FA, Sole CV, Atahualpa F, et al. Chemoradiation for resected pancreatic adenocarcinoma with or without intraoperative radiation therapy boost: long-term outcomes. Pancreatology. 2013;13:576–82.PubMedCrossRef
23.
Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128–37.PubMedCrossRef
24.
Dubois JB, Bussieres E, Richaud P, et al. Intra-operative radiotherapy of rectal cancer: results of the French multi-institutional randomized study. Radiother Oncol. 2011;98:298–303.PubMedCrossRef
25.
Kusters M, Valentini V, Calvo FA, et al. Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol. 2010;21:1279–84.PubMedCrossRef
26.
Dresen RC, Gosens MJ, Martijn H, et al. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer. Ann Surg Oncol. 2008;15:1937–47.PubMedCentralPubMedCrossRef
27.
Mirnezami R, Chang GJ, Das P, et al. Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol. 2013;22:22–35.PubMedCrossRef
28.
Alberda WJ, Verhoef C, Nuyttens JJ, et al. Intraoperative radiation therapy reduces local recurrence rates in patients with microscopically involved circumferential resection margins after resection of locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2014;88:1032–40.PubMedCrossRef
29.
Calvo FA, Sole CV, Serrano J, et al. Postchemoradiation laparoscopic resection and intraoperative electron-beam radiation boost in locally advanced rectal cancer: long-term outcomes. J Cancer Res Clin Oncol. 2013;139:1825–33.PubMedCrossRef
30.
Haddock MG, Miller RC, Nelson H, et al. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011;79:143–50.PubMedCrossRef
31.
Calvo FA, Sole CV, Alvarez de Sierra P, et al. Prognostic impact of external beam radiation therapy in patients treated with and without extended surgery and intraoperative electrons for locally recurrent rectal cancer: 16-year experience in a single institution. Int J Radiat Oncol Biol Phys. 2013;86:892–900.PubMedCrossRef
32.
James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24.PubMedCrossRef
33.
Wright JL, Gollub MJ, Weiser MR, et al. Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. Dis Colon Rectum. 2011;54:1090–7.PubMedCrossRef
34.
Hallemeier CL, You YN, Larson DW, et al. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum. 2014;57:442–8.PubMedCrossRef
35.
Zhang Q, Tey J, Yang Z, et al. Intraoperative radiotherapy in the combination of adjuvant chemotherapy for the treatment of pT3N0M0 rectal cancer after radical surgery. Am J Clin Oncol. 2014;37:8–12.
Metadata
Title
Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy
Authors
Felipe A. Calvo
Claudio V. Sole
Hugo Marsiglia
Eduardo Alvarado
Carlos Ferrer
Brian Czito
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 1/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-014-0419-8

Other articles of this Issue 1/2015

Current Oncology Reports 1/2015 Go to the issue

Head and Neck Cancers (E Hanna, Section Editor)

Prognosis and Biology in Esthesioneuroblastoma: the Emerging Role of Hyams Grading System

Head and Neck Cancers (E Hanna, Section Editor)

Defining Value-Driven Care in Head and Neck Oncology

Head and Neck Cancers (E Hanna, Section Editor)

Body Image: a Critical Psychosocial Issue for Patients With Head and Neck Cancer

Gastrointestinal Cancers (B Czito, Section Editor)

Endoscopic Approaches for Early-Stage Esophageal Cancer: Current Options

Gastrointestinal Cancers (B Czito, Section Editor)

Update on Treatment of Liver Metastases: Focus on Ablation Therapies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits